(EOLS) and the Role of Price-Sensitive Allocations
This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) based on AI-generated signals for July 7, 2026. It highlights a near-term weak sentiment but mid-term strength within a broader long-term weak bias, noting compelling upside potential due to the absence of resistance levels above the current price. The analysis includes institutional trading strategies with specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging, alongside a multi-timeframe signal analysis.
EOLS - Evolus Inc Options
This page provides a detailed financial overview of Evolus Inc (EOLS) options, including its latest stock price, financial metrics, and performance indicators. It covers market capitalization, income, sales, various ratios, insider ownership, institutional ownership, profitability, and stock performance over different periods. The data also highlights short interest, volatility, and analyst recommendations.
Enterprise value to EBITDA forward of Evolus, Inc. Common Stock – NASDAQ:EOLS
This page from TradingView provides financial information for Evolus, Inc. Common Stock (NASDAQ: EOLS), specifically focusing on its enterprise value to EBITDA forward metric. It highlights the company's financial overview within the health technology and pharmaceutical sectors. The content presented is a data point from TradingView's financial analysis tools.
Evolus (EOLS) price target decreased by 11.11% to 14.96
The price target for Evolus (EOLS) has been decreased by 11.11%, bringing it down to $14.96. Further details are not available in the provided content.
Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS)
This article provides actuals and estimates for Evolus, Inc. (NASDAQ:EOLS), including financial data, analyst forecasts, and various stock performance metrics. It covers the company's current stock price, historical highs and lows, volatility, market capitalization, and earnings information, alongside answers to frequently asked questions about investing in EOLS.
Price to sales forward of Evolus, Inc. Common Stock – NASDAQ:EOLS
This article provides access to the "Price to sales forward" financial metric for Evolus, Inc. Common Stock (NASDAQ: EOLS) on the TradingView platform. It highlights that this data is part of the financials section for EOLS, indicating its availability for users analyzing the company's stock performance. The content itself is a placeholder for accessing this specific financial metric.
EOLS Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Evolus, Inc. (EOLS) stock for 2027, based on analyst ratings and the company's financial performance. It includes current stock price information, historical highs and lows, market capitalization, volatility, and details on earnings reports and revenue. The analysis also covers technical ratings and answers frequently asked questions about EOLS.
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Evolus Inc (EOLS), detailing its price momentum score of 9.32 within the Pharmaceuticals industry. It identifies current support at $6.35 and resistance at $7.55, suggesting suitability for range-bound swing trading. The analysis includes a summary of technical indicators and moving averages, with a consensus "Buy" signal based on these metrics.
Is Evolus (EOLS) Finally Turning the Corner on Profitability
Evolus (EOLS) reported strong Q1 2026 results, beating revenue expectations with $73.1 million, driven by demand for Jeuveau and growth in Evolisse. The company achieved its second consecutive quarter of positive Adjusted EBITDA, signaling progress toward full-year profitability despite a net loss. Strategic international expansion and upcoming product launches are expected to support sustained double-digit growth and improved operating leverage by 2028.
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis
Evolus Inc (EOLS) has a financial score of 8.00, placing it 84th out of 157 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a quarterly revenue of $73.14M, marking a 6.74% year-over-year increase, and net profit increased by 43.50% year-over-year. Key financial indicators like cash and cash equivalents, total assets, and cash flow from operating activities are yet to be disclosed by the company.
Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Evolus Inc (EOLS). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays current stock information for EOLS, including its market capitalization.
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Evolus Inc (EOLS), identifying major shareholders by proportion and type, as well as institutional holdings over various quarters. It highlights key individual and institutional investors and their recent activities, alongside related ETF holdings.
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Evolus Inc (EOLS) has an earnings forecast score of 8.57, ranking 28th in the Pharmaceuticals industry. Analysts have a consensus "Buy" rating for EOLS, with an average price target of $19.50, suggesting a significant upside of over 121% from its current price of $6.63. The expected revenue for the next quarter is $81.95 million.
EOLS Reiterated by BTIG -- Price Target Maintained at $13.00
BTIG has reiterated a Buy rating for Evolus (EOLS), maintaining a price target of $13.00. Despite strong growth potential (GF Score Growth 10/10), the company faces challenges in Financial Strength and Profitability (both 3/10). The stock is considered 51.0% undervalued by GuruFocus, but recent insider selling of $797,184 warrants caution for investors.
Evolus Inc (EOLS) Institutional Confidence
Evolus Inc (EOLS) has an institutional shareholding score of 7.00, ranking 51st in the Pharmaceuticals industry. The institutional shareholding proportion is 75.98%, a decrease of 14.84% quarter-over-quarter. James Simons is the largest institutional shareholder, with other significant holders including Timothy Patrick Lynch, Nantahala Capital Management, and BlackRock Institutional Trust Company.
[EFFECT] Evolus, Inc. SEC Filing
This article provides details on an SEC filing (Form EFFECT) by Evolus, Inc. The filing indicates an effectiveness date of June 12, 2026, for Form S-3. It also includes company information, recent news, and other SEC filings for Evolus.
Understanding the Setup: (EOLS) and Scalable Risk
This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) using AI models to suggest trading strategies. It highlights mixed sentiment, potential upside due to lack of resistance, and offers specific position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal data for various risk profiles.
Evolus shareholders re-elect directors and approve executive compensation
Evolus Inc. shareholders re-elected Brady Stewart and Vikram Malik as Class II directors for three-year terms and ratified Ernst & Young LLP as the independent public accounting firm. Shareholders also approved the compensation of the company’s named executive officers in an advisory vote. The company, listed on Nasdaq under EOLS, recently reported mixed Q1 2026 earnings and announced the upcoming European launch of its Estyme dermal filler line.
Evolus (EOLS) shareholders approve directors, auditor and say-on-pay at 2026 meeting
At its Annual Meeting of Stockholders held on June 11, 2026, Evolus, Inc. (EOLS) shareholders elected Brady Stewart and Vikram Malik as Class II directors, with terms extending until the 2029 annual meeting. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers. These decisions were formally reported in an 8-K filing.
Evolus (EOLS) Jefferies Global Healthcare Conference 2026 Summary
Evolus (EOLS) presented at the Jefferies Global Healthcare Conference 2026, highlighting its transition from a single-product neurotoxin company to a diversified aesthetics portfolio with expanded international presence and significant digital platform growth. The company emphasized its innovative HA injectable line, Evolysse, and upcoming products like Sculpt, noting strong market trends such as younger demographics' embrace of aesthetics and increased demand from GLP-1 weight loss drug users. Evolus also detailed its focus on building clinic partnerships and driving profitability through digital efficiencies and a portfolio approach.
Evolus (NASDAQ: EOLS) registers $250M shelf; $195.5M unsold re‑registered
Evolus, Inc. has filed an S-3 shelf registration statement to replace an expiring one, re-registering $195.5 million of previously unsold securities and authorizing the offer of up to $250 million in new common stock, preferred stock, debt securities, warrants, units, and rights. This filing allows Evolus flexibility to raise capital as needed, with specific terms for future offerings to be detailed in prospectus supplements. The company's common stock is listed on Nasdaq under the symbol EOLS, and the last reported sale price was $6.60 per share.
The Technical Signals Behind (EOLS) That Institutions Follow
This article from Stock Traders Daily analyzes the technical signals for Evolus Inc. (NASDAQ: EOLS), noting weak sentiment across all horizons which supports a short bias. It identifies no resistance levels above the current price, suggesting upside potential. The piece provides details on AI-generated trading strategies for different risk profiles, including long, breakout, and short positions with specific entry, target, and stop-loss levels.
Evolus Shareholder Notice
Faruqi & Faruqi, LLP is investigating potential claims against Evolus, Inc. (NASDAQ: EOLS) and encouraging investors who lost over $100,000 between February 1, 2019, and July 6, 2020, to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Evolus made false statements regarding the misappropriation of a botulinum toxin strain and manufacturing processes from Medytox, leading to regulatory threats and a significant stock drop after an ITC ruling.
Evolus Update
Faruqi & Faruqi, LLP is investigating potential claims against Evolus, Inc. (NASDAQ:EOLS) and encouraging investors who lost over $100,000 to contact them. The investigation follows findings by the U.S. International Trade Commission that Evolus misappropriated trade secrets related to its Jeuveau™ product, leading to a significant drop in the company's stock price. Investors have until December 15, 2020, to seek the role of lead plaintiff in the federal securities class action lawsuit.
Precision Trading with Evolus Inc. (EOLS) Risk Zones
This article provides a detailed AI-driven analysis of Evolus Inc. (EOLS) with a focus on risk zones and trading strategies. It highlights mixed sentiment across different time horizons, suggesting choppy market conditions. The analysis offers specific position trading, momentum breakout, and risk hedging strategies, complete with entry points, targets, and stop losses.
Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus, Inc. announced its management team will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference in New York City. The fireside chat is scheduled for June 4, 2026, at 12:50 PM ET and will be accessible via webcast on the Evolus Investor Relations page. Evolus is a performance beauty company focused on aesthetic injectables with products like Jeuveau® and Evolysse™.
Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus, Inc. (NASDAQ: EOLS) announced that its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City on June 4th, 2026. The company, a performance beauty leader, will have its fireside chat accessible via webcast on its investor relations page, with a replay available for 90 days. Evolus aims to redefine the aesthetic injectable market with products like Jeuveau® and Evolysse™.
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises
Evolus Inc. reported a Q1 2026 EPS miss at -$0.16 against a -$0.11 forecast, but revenue slightly exceeded expectations at $73.1 million. Despite the EPS shortfall, the company's stock experienced a significant 19.51% increase in after-hours trading, driven by strong revenue growth and positive Adjusted EBITDA. Evolus reiterated its full-year 2026 guidance, expecting continued double-digit revenue growth and Adjusted EBITDA profitability, with upcoming product launches like Estyme in Europe and anticipated FDA approval for Sculpt.
Evolus To Roll Out Estyme Injectable Hyaluronic Acid Fillers in Europe
Evolus, Inc. announced the official launch of its Estyme injectable hyaluronic acid (HA) gel collection in Europe on May 16, 2026. The collection includes four HA gels, with Estyme Smooth and Estyme Form already marketed in the U.S. as Evolysse, and the debut of Estyme Lips and Estyme Sculpt for Europe. This launch follows CE Mark certification and positions Evolus as a multi-product aesthetics company, particularly with the potential leader Estyme Sculpt for mid-face volumizing.
Evolus (EOLS) to Launch Estyme Injectable Collection in Europe
Evolus Inc. (EOLS) announced the upcoming launch of its Estyme line of injectable hyaluronic acid gels in Europe on May 16th, marking its entry into the global dermal filler market. While this expansion presents a significant growth opportunity for Evolus, the company also exhibits notable financial weaknesses and a trend of insider selling, urging caution for potential investors. Evolus has a GF Score™ of 62/100, indicating moderate overall performance, but shows strong growth potential alongside poor financial strength and profitability ratings.
Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe
Evolus Inc. (EOLS) announced the commercial launch of its Estyme® injectable hyaluronic acid gels in Europe. This marks a significant expansion for the company into the European aesthetics market. The product is designed to offer a new option for patients seeking hyaluronic acid-based aesthetic treatments.
Evolus May 2026 slides: HA innovation, Jeuveau data support dual strategy
Evolus Inc. presented comprehensive clinical data for its Evolysse hyaluronic acid filler line, featuring its proprietary Cold-X™ Technology, and its Jeuveau neuromodulator. The company highlighted strong efficacy and safety profiles for both product lines in various aesthetic indications, including statistical superiority for Evolysse Form against a comparator. Evolus also discussed an extra-strength Jeuveau formulation and outlined its commercial roadmap for upcoming product launches, reinforcing its dual-product strategy and positive market outlook.
Earnings call transcript: Evolus Inc Q1 2026 misses EPS forecast, stock rises
Evolus Inc. (NASDAQ:EOLS) reported its Q1 2026 earnings, missing EPS forecasts but exceeding revenue expectations with $73.1 million. The stock surged 19.51% in after-hours trading, driven by a 7% year-over-year revenue increase and a second consecutive quarter of positive Adjusted EBITDA, despite an EPS of -$0.16 against a -$0.11 forecast. The company reiterated its full-year 2026 guidance for revenue and profitability, expressing confidence in its strategic priorities and market recovery for aesthetic products.
Evolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery Gaps
Evolus, Inc. (EOLS) is exposed to significant operational risks due to its reliance on overseas third-party manufacturers, which could lead to supply disruptions, affect clinical development, and harm the company financially and reputationally. The company also faces potential issues from inadequate disaster recovery and business continuity plans, which could result in substantial costs and prolonged downtime. Analysts currently project a 127.63% upside potential for EOLS stock, with an average price target of $14.50.
Evolus, Inc. (NASDAQ:EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. reported strong Q1 2026 results, exceeding earnings expectations and achieving positive adjusted EBITDA for the second consecutive quarter. The company maintained Jeuveau's U.S. market share at 14% and delivered share gains with Evolisse, emphasizing its differentiated commercial model and leveraging AI for efficiency. Evolus reiterated its full-year 2026 outlook, projecting double-digit revenue growth and full-year adjusted EBITDA profitability, while also planning for the international launch of Esteem and FDA approval for Sculp.
Evolus Posts Mixed Q1 Results
Evolus Inc. reported mixed first-quarter results, exceeding revenue expectations with a 7% increase to $73.1 million, but also posting a wider net loss of 16 cents compared to an anticipated 11-cent loss. The aesthetics company, known for its product Jeuveau, reaffirmed its full-year revenue guidance of $327 million to $337 million, representing 10% to 13% growth. Following the announcement, Evolus shares saw a slight rise in after-hours trading.
Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary
Evolus, Inc. reported its first-quarter 2026 results, showing a 6.7% year-over-year revenue increase to $73.14M and a reduction in net loss to ($10.67M). Diluted loss per share improved to ($0.16) compared to ($0.3) in the prior year. This growth was attributed to the Evolysse® launch and the international expansion of Jeuveau® in various markets.
Evolus Inc. (EOLS) stock falls on Q1 2026 Earnings
Evolus Inc. (EOLS) reported Q1 2026 revenue of $73.1 million, below analyst estimates, leading to a stock decline. The company experienced a decrease in net income, diluted EPS, and cash from operating activities year-over-year. Insider selling and significant hedge fund activity, including both reductions and additions to positions, were also noted.
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus, Inc. reported its first-quarter 2026 financial results, achieving its second consecutive quarter of positive Adjusted EBITDA with $0.6 million and global net revenue of $73.1 million, a 7% increase year-over-year. The company reaffirmed its full-year 2026 net revenue guidance of $327 million to $337 million and anticipates achieving a low- to mid-single-digit Adjusted EBITDA margin in 2026. This performance was driven by strong demand for Jeuveau® and growing momentum for Evolysse®, along with an expanding loyalty program and strategic international launches.
Evolus (NASDAQ: EOLS) Q1 2026 earnings, guidance and growth outlook
Evolus (NASDAQ: EOLS) reported Q1 2026 net revenue of $73.1 million, a 7% increase year-over-year, and achieved positive Adjusted EBITDA of $0.6 million for the second consecutive quarter. The company reaffirmed its full-year 2026 net revenue guidance of $327–$337 million and a low- to mid-single digit Adjusted EBITDA margin, while also setting a long-term target of $450–$500 million in revenue and 13–15% Adjusted EBITDA margins by 2028. Evolus noted potential impacts from a proposed 15% U.S. tariff on patented pharmaceuticals from South Korea but expressed confidence in mitigating near- to medium-term effects.
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus, Inc. reported its first-quarter 2026 financial results, highlighting a second consecutive quarter of positive Adjusted EBITDA, reaching $0.6 million. The company reaffirmed its full-year 2026 net revenue guidance of $327 million to $337 million and non-GAAP operating expenses of $210 million to $216 million, expecting to achieve a low- to mid-single-digit Adjusted EBITDA margin. These results reflect continued business strength, structural improvements, and growing customer engagement with its Jeuveau® and Evolysse® products, alongside strategic portfolio expansion.
Evolus Q1 2026 earnings preview
This article provides a preview of Evolus's Q1 2026 earnings. As a medical aesthetics company, its performance is often watched for insights into the growth of the cosmetic treatment market. Investors will be keen to see if the company's financial results meet expectations.
Evolus Inc expected to post a loss of 13 cents a share - Earnings Preview
Evolus Inc (EOLS) is projected to report a loss of 13 cents per share, according to a recent earnings preview. This forecast comes from Refinitiv. The article provides a brief update on the company's expected financial performance.
[ARS] Evolus, Inc. SEC Filing
This article announces an ARS SEC filing by Evolus, Inc. (EOLS) with a neutral sentiment and low impact. The filing was accepted on April 29, 2026, and is available as a PDF document. The article also provides a brief overview of Evolus, including its market cap ranking and recent news and SEC filings.
Evolus Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Evolus, Inc. (NASDAQ: EOLS) and reminds investors of the December 15, 2020 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Evolus misappropriated trade secrets regarding its botulinum toxin product, Jeuveau™, leading to a significant drop in stock price after a U.S. International Trade Commission ruling. Investors who suffered losses exceeding $100,000 between February 1, 2019, and July 6, 2020, are encouraged to contact the firm.
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of "Moderate Buy" by Analysts
Evolus, Inc. (NASDAQ:EOLS) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month target price of $16.00. The company recently reported Q4 earnings where revenue exceeded expectations at $90.3 million, though EPS was $0.00 against an anticipated $0.09. Insiders have sold a total of 163,504 shares worth $797,184 in the past 90 days, yet institutional investors hold a significant 90.69% of the stock.
Evolus (NasdaqGM:EOLS) Stock Forecast & Analyst Predictions
Evolus (NasdaqGM:EOLS) is forecast to significantly grow earnings and revenue over the next few years, with EPS expected to increase by 64.9% per annum. Despite this positive outlook, analysts have recently lowered their price targets on Evolus due to adjusted assumptions regarding long-term revenue growth and more conservative guidance for 2025 and 2026. The company is expected to become profitable within the next three years, outpacing the savings rate and the broader market growth.
Short Interest in Evolus, Inc. (NASDAQ:EOLS) Drops By 14.4%
Evolus, Inc. (NASDAQ:EOLS) experienced a 14.4% decrease in short interest in March, totaling 6,517,006 shares by March 31st, which represents 10.6% of its stock and a 6.6-day short-interest ratio. Insider sales also occurred, with David Moatazedi selling 116,720 shares and Rui Avelar selling 29,996 shares, reducing their ownership. Despite institutional ownership being high at 90.69% and a "Moderate Buy" consensus from analysts with a $16 price target, the stock is trading near $4.69 following a recent EPS miss.
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript
This entry indicates the availability of the Q4 2025 earnings call transcript for Evolus, Inc. (NASDAQ:EOLS). This crucial document provides a detailed overview of the company's financial performance and strategic outlook discussed during the call. Investors and analysts can use this resource to gain insights into the company's recent results and future plans.
Evolus (LTS:0K16) PB Ratio : (As of Apr. 10, 2026)
This article from GuruFocus examines Evolus (LTS:0K16) Price-to-Book (PB) Ratio as of April 11, 2026. It elaborates on the calculation of the PB Ratio, provides historical data and industry comparisons, and notes that Evolus' stock appears to be undervalued according to GuruFocus' GF Value™. The company's business description highlights its focus on aesthetic medicine with its flagship product, Jeuveau.
